NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City
May 04 2023 - 6:45AM
(via IBN) -- NanoViricides, Inc. (NYSE
American: NNVC)
(the “Company”), a clinical stage global leader in the development
of highly effective antiviral therapies based on a novel
nanomedicines platform, announces that Anil R. Diwan, Ph.D.,
President of the Company will be presenting at The Inaugural EF
Hutton Global Conference, which will be held on May 10-11, 2023, at
the Plaza Hotel in the heart of New York City. NanoViricides is
presenting on May 10th.
Event |
The Inaugural EF
Hutton Global Conference |
Date |
May 10-11,
2023 |
Format |
1 x 1
meetings |
Location |
The Plaza Hotel, New
York City |
The Inaugural EF Hutton Global Conference is a
two-day, invitation-only event featuring key executives from
approximately 150 public and private companies to convey their
unique stories to an extensive audience that includes institutional
investors, high-net worth individuals, corporate clients and
exclusive members of the press.
To learn more, visit
https://ibn.fm/EFHutton2023Conference
A wide variety of sectors will be represented,
including Consumer and Retail, Energy and Infrastructure, Financial
Services, Healthcare and Life Sciences, Industrials, Real Estate,
Gaming, Lodging, Sustainability, Technology, Media and
Telecommunications. Up to 8 meetings will be selected each day and
one-on-one interactive sessions will be provided. The conference
will offer companies a novel forum to create, amplify, cross-sell
and highlight communications between corporate executives, industry
experts and investors across the EF Hutton Platform.
About EF HuttonEF Hutton, division of Benchmark
Investments, LLC, is a global, full-service investment bank
headquartered in New York, New York. EF Hutton is a division of
Benchmark Investments, LLC, a subsidiary of Kingswood US, LLC, an
indirect subsidiary of Kingswood Holdings Limited (AIM: KWG). The
synergies and direct access to Kingswood Holdings Limited provide
EF Hutton with a unique global presence and broad platform outreach
to ensure success for its clients.
ABOUT NANOVIRICIDES, INC.
NanoViricides, Inc. (the "Company”) (http://www.nanoviricides.com)
is a clinical stage company that is creating special purpose
nanomaterials for antiviral therapy. The Company's novel
nanoviricide® class of drug candidates are designed to specifically
attack enveloped virus particles and to dismantle them. Each
nanoviricide drug is designed so that virus variants would be
highly unlikely to escape the drug, solving a critical issue in
antiviral drug development.
Our lead drug candidate for the treatment of
COVID and long COVID caused by SARS-CoV-2 coronavirus is approved
to enter human clinical trials that are expected very soon. Our
other advanced candidate is NV-HHV-1 for the treatment of Shingles,
which has completed IND-enabling safety/pharmacology studies.
NV-CoV-2 is the Company’s nanoviricide drug
candidate for COVID. NV-CoV-2-R is another drug candidate for COVID
that is made up of NV-CoV-2 with Remdesivir, an already approved
drug, encapsulated within its polymeric micelles. Remdesivir is
developed by Gilead. The Company has developed both of its own drug
candidates NV-CoV-2 and NV-CoV-2-R independently. The Company
cannot project exact dates for the regulatory activities in
progressing its drug candidates because of the Company’s
significant dependence on external collaborators and
consultants.
The Company is also developing a broad pipeline
of drugs against a number of viruses, with preclinical safety and
effectiveness successes achieved already in many cases.
NanoViricides’ platform technology and programs are based on the
TheraCour® nanomedicine technology of TheraCour, which TheraCour
licenses from AllExcel. NanoViricides holds a worldwide exclusive
perpetual license to this technology for several drugs with
specific targeting mechanisms for the treatment of the following
human viral diseases: Human Immunodeficiency Virus (HIV/AIDS),
Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes
Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV),
Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese
Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and
certain Coronaviruses. The Company intends to obtain a license for
poxviruses, enteroviruses, and other viruses that it engages into
research for, if the initial research is successful. TheraCour has
not denied any licenses requested by the Company to date. The
Company’s business model is based on licensing technology from
TheraCour Pharma Inc. for specific application verticals of
specific viruses, as established at its foundation in 2005.
Disclosure StatementThis press release contains
forward-looking statements that reflect the Company's current
expectation regarding future events. Actual events could differ
materially and substantially from those projected herein and depend
on a number of factors. Certain statements in this release, and
other written or oral statements made by NanoViricides, Inc. are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. You should not place undue reliance on
forward-looking statements since they involve known and unknown
risks, uncertainties and other factors that are, in some cases,
beyond the Company's control and that could, and likely will,
materially affect actual results, levels of activity, performance
or achievements. The Company assumes no obligation to publicly
update or revise these forward-looking statements for any reason,
or to update the reasons actual results could differ materially
from those anticipated in these forward-looking statements, even if
new information becomes available in the future. Important factors
that could cause actual results to differ materially from the
company's expectations include, but are not limited to, those
factors that are disclosed under the heading "Risk Factors" and
elsewhere in documents filed by the company from time to time with
the United States Securities and Exchange Commission and other
regulatory authorities. Although it is not possible to predict or
identify all such factors, they may include the following:
demonstration and proof of principle in preclinical trials that a
nanoviricide is safe and effective; successful development of our
product candidates; our ability to seek and obtain regulatory
approvals, including with respect to the indications we are
seeking; the successful commercialization of our product
candidates; and market acceptance of our products. In particular,
as is customary, the Company must state the risk factor that the
path to typical drug development of any pharmaceutical product is
extremely lengthy and requires substantial capital. As with any
drug development efforts by any company, there can be no assurance
at this time that any of the Company’s pharmaceutical candidates
would show sufficient effectiveness and safety in human clinical
trials to lead to a successful pharmaceutical product, including
our coronavirus drug development program.
ICH refers to The International Council for
Harmonisation of Technical Requirements for Pharmaceuticals for
Human Use. FDA refers to US Food and Drug Administration. IND
application refers to “Investigational New Drug” application. cGMP
refers to current Good Manufacturing Practices. CMC refers to
“Chemistry, Manufacture, and Controls”. CHMP refers to the
Committee for Medicinal Products for Human Use, which is the
European Medicines Agency's (EMA) committee responsible for human
medicines. API stands for “Active Pharmaceutical Ingredient”.
Contact:NanoViricides,
Inc.info@nanoviricides.com
Public Relations Contact:MJ
Clyburn TraDigital IR clyburn@tradigitalir.com
Wire Service Contact:InvestorWire (IW)Los
Angeles, Californiawww.InvestorWire.com 212.418.1217
Officeeditor@InvestorWire.com
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Jul 2023 to Jul 2024